| 1 |
33609419 | Impact of diabetes on promoting the growth of breast cancer. | 2021 May |
2 |
| 2 |
33613693 | Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. | 2021 |
1 |
| 3 |
34374879 | Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study. | 2021 Nov |
1 |
| 4 |
31474154 | Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules. | 2020 |
1 |
| 5 |
33108409 | Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. | 2020 |
1 |
| 6 |
30536182 | Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. | 2019 Apr |
1 |
| 7 |
30610588 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. | 2019 Apr |
3 |
| 8 |
31118051 | PYK2 promotes HER2-positive breast cancer invasion. | 2019 May 22 |
9 |
| 9 |
31395589 | Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. | 2019 Nov |
1 |
| 10 |
30479698 | A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. | 2018 Nov 2 |
1 |
| 11 |
28126011 | Metformin targets multiple signaling pathways in cancer. | 2017 Jan 26 |
1 |
| 12 |
28375706 | Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. | 2017 May 1 |
3 |
| 13 |
25916213 | Association of diabetes and diabetes treatment with incidence of breast cancer. | 2016 Feb |
1 |
| 14 |
26581908 | Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. | 2016 May |
8 |
| 15 |
26728433 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. | 2016 Jan 5 |
2 |
| 16 |
25351941 | Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells. | 2015 Jul |
4 |
| 17 |
25935404 | Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. | 2015 May 3 |
1 |
| 18 |
26276754 | Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. | 2015 Oct |
6 |
| 19 |
26625311 | Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. | 2015 Dec 29 |
7 |
| 20 |
24322659 | Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. | 2014 Feb |
7 |
| 21 |
24716971 | Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study. | 2014 |
1 |
| 22 |
25051360 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. | 2014 Jul 15 |
1 |
| 23 |
23292119 | Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. | 2013 Feb |
1 |
| 24 |
23613388 | Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90. | 2013 Jan-Mar |
4 |
| 25 |
24107633 | Glucose promotes breast cancer aggression and reduces metformin efficacy. | 2013 Dec 15 |
2 |
| 26 |
22112968 | Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. | 2012 Jul |
2 |
| 27 |
22333588 | Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. | 2012 Mar 1 |
2 |
| 28 |
22565037 | Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. | 2012 Apr |
2 |
| 29 |
22593441 | Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. | 2012 May |
1 |
| 30 |
22809961 | Metformin is synthetically lethal with glucose withdrawal in cancer cells. | 2012 Aug 1 |
1 |
| 31 |
20458531 | The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. | 2011 Apr |
4 |
| 32 |
21862872 | Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. | 2011 Sep 1 |
6 |
| 33 |
22203527 | Metformin: multi-faceted protection against cancer. | 2011 Dec |
1 |
| 34 |
19884247 | Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. | 2010 Jan |
1 |
| 35 |
20465505 | Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. | 2010 May |
1 |
| 36 |
19106626 | The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. | 2009 Jan 1 |
15 |
| 37 |
19153119 | The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. | 2009 Mar |
1 |
| 38 |
19221498 | Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. | 2009 Mar 15 |
8 |
| 39 |
19560877 | Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. | 2009 Oct |
3 |
| 40 |
19574203 | mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). | 2009 Jul |
2 |